At Center for Breakthrough Medicines, our mission is to save lives by accelerating the development and manufacturing of advanced therapies.
Our fully integrated services include drug substance and drug product for all phases of the product lifecycle at a single site.
CBM is the Exclusive CDMO Provider of an iCellis 500-based
Adeno-Associated Virus (AAV) Adherent Platform developed by the Gene Therapy Program at the University of Pennsylvania
Cell One Partners and Center for Breakthrough Medicines Announce Strategic Partnership to Accelerate Cell and Gene Therapy CommercializationMarch 9, 2023
Center for Breakthrough Medicines, Nucleus Biologics, and Stoic Bio Announce Strategic Collaboration for Steady Supply of Quality Controlled Cell Culture Media to Expedite Development of Cell and Gene TherapiesMarch 7, 2023
Center for Breakthrough Medicines Offers Pre-clinical Packages with Plasmids, Cell Line, and Pre-clinical Vector Manufacturing with Capacity Available NowFebruary 28, 2023
Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing critical challenges associated with the commercialization of cell and gene therapies, and Virion Therapeutics (Virion), a clinical-stage biotech company focuFebruary 22, 2023
The Center for Breakthrough Medicines (CBM), a contract development, and manufacturing organization (CDMO) has launched their plasmid manufacturing offering, Precision PlasmidsTM to provide phase-appropriate plasmid on-demand to accelerate the path to clinic for cell and gene therapies.February 2, 2023
Our empowering culture supports people committed to transforming patients’ lives.Learn More >
CBM is led by an amazing team. Discover the caliber of people you will work with.Learn more >